Peninsula company's fix for deviated septum greenlighted by FDA

The 16-person company looks to slowly commercialize its system for fixing minor nasal septal deviations and raise a $25 million to $30 million Series B round.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news